See also this year's filing and all EDGAR filings for this company.
PDF Report 0001638287_2020_NeuroBo_Pharmaceuticals_Inc.pdf
Logs
warning | Missing logo | subcommand.report | {} |
info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Assets', 'missing_ratio': 0.001661589587371919, 'aggregate_val': 14468000, 'exp_sum': 14444000, 'exp_to_value': {'AssetsCurrent': 14118000, 'IntangibleAssetsNetIncludingGoodwill': 0, 'PropertyPlantAndEquipmentNet': 200000, 'remainder_Assets': 126000}} |
info | Failed to set obs_EconomicCapitalRatio | industry.us_generic | {'reason': "KeyError('0001638287')"} |
info | Ambiguous roles for statement | input.sec.calculation_linkbase.expand_agg | {'statement': 'operations', 'valid_roles': {'00200 - Statement - Consolidated Statements of Operations and Comprehensive Loss': 10, '00205 - Statement - Condensed Statements of Comprehensive Loss (Calc 2)': 2}} |
info | Added remainder_ComprehensiveNetIncome directly from 10K | industry.us_generic | {} |
Graph
Absolute values for 0001638287, NeuroBo Pharmaceuticals Inc.
xvar | xval | |
---|---|---|
0 | AssetsCurrent | 14,118,000 |
1 | IntangibleAssetsNetIncludingGoodwill | 0 |
2 | PropertyPlantAndEquipmentNet | 200,000 |
3 | remainder_Assets | 150,000 |
4 | LiabilitiesCurrent | 2,082,000 |
5 | LiabilitiesNoncurrent | 0 |
6 | remainder_Liabilities | 94,000 |
7 | CostOfGoodsAndServicesSold | 0 |
8 | SellingGeneralAndAdministrativeExpense | 2,701,000 |
9 | ResearchAndDevelopmentExpense | 17,475,000 |
10 | remainder_Expenses | 0 |
11 | remainder_Revenues | 0 |
12 | remainder_NetIncome | -1,136,000 |
13 | remainder_ComprehensiveNetIncome | 10,000 |
yvar | yval | |
---|---|---|
0 | Assets | 14,468,000 |
1 | Liabilities | 2,176,000 |
2 | Expenses | 20,176,000 |
3 | Revenues | 0 |
4 | StockholdersEquity | 12,292,000 |
5 | NetIncome | -21,312,000 |
6 | ComprehensiveNetIncome | -21,307,000 |
7 | BaseVar | 18,983,000 |
8 | EconomicCapitalRatio | -0.0198 |